NYSE:PTHN Patheon N.V. Ordinary shares, p (PTHN) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free PTHN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$34.98▼$34.9850-Day Range N/A52-Week Range$23.72▼$35.13VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Patheon N.V. Ordinary shares, p alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Patheon N.V. Ordinary shares, p Stock (NYSE:PTHN)Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) PTHN Stock News HeadlinesMarch 19, 2024 | money.usnews.comChain Bridge I - Ordinary Shares - Class AFebruary 28, 2024 | nasdaq.comYandex N.V. Class A Ordinary Shares (YNDX)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 27, 2024 | money.usnews.comAon plc. - Ordinary Shares - Class AFebruary 23, 2024 | morningstar.comThe Kingfish Co NV Ordinary Shares KINGFebruary 21, 2024 | money.usnews.comKinder Morgan Inc - Ordinary Shares - Class PFebruary 14, 2024 | morningstar.comJDE Peets NV Ordinary SharesDecember 12, 2023 | nasdaq.comEaton Corporation, PLC Ordinary Shares (ETN)March 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.December 2, 2023 | morningstar.comIveco Group NV Ordinary SharesNovember 14, 2023 | finance.yahoo.comPatheon N.V. Ordinary shares, p (PTHN)November 13, 2023 | lse.co.ukEase2pay Nv Share Price (EAS2P.AM)November 11, 2023 | lse.co.ukNew Amsterdam Invest N.v. Ordinary Shares Share ChatOctober 29, 2023 | morningstar.comInPoint Commercial Real Estate Income Inc Ordinary Shares - Class PSeptember 28, 2023 | morningstar.comWallbox NV Class A Ordinary ShareSeptember 1, 2023 | money.usnews.comCrowdstrike Holdings Inc - Ordinary Shares - Class AAugust 16, 2023 | money.usnews.comXPEL Inc - Ordinary Shares - Reg SAugust 15, 2023 | morningstar.comCureVac NV Ordinary SharesAugust 4, 2023 | health.usnews.comKeesha P. KaplanJuly 31, 2023 | nasdaq.comLifezone Metals Limited Ordinary Shares (LZM)July 21, 2023 | uk.investing.comFT Ordinary Share (FTII)July 19, 2023 | nasdaq.comNewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)June 28, 2023 | money.usnews.comComcast Corp - Ordinary Shares - Class AJune 19, 2023 | finance.yahoo.comImproved Earnings Required Before RoodMicrotec N.V. (AMS:ROOD) Shares Find Their FeetApril 29, 2023 | morningstar.comZhongAn Online P&C Insurance Co Ltd Ordinary Shares - Class HApril 4, 2023 | thestreet.comS&P, Moody's Shares Surge on Fraud Lawsuit SettlementMarch 31, 2023 | nasdaq.comNIO Inc. American depositary shares, each representing one Class A ordinary share (NIO)See More Headlines Receive PTHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Patheon N.V. Ordinary shares, p and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/08/2017Today3/28/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:PTHN Previous SymbolNASDAQ:PTHN CUSIPN/A CIK1643848 Webwww.patheon.com Phone31-20-622-3243FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesPaul S. LevyChairman of the BoardJames C. MullenChief Executive Officer, DirectorStuart R. GrantChief Financial Officer, Executive Vice PresidentGilles A. CottierPresident - Global Pharmaceutical Development ServicesFranco NegronPresident - Drug Product ServicesLukas UtigerPresident - Drug SubstanceMichael J. LehmannExecutive Vice President - Global Sales and MarketingMichael E. Lytton J.D.Executive Vice President - Corporate Development and StrategyRebecca Holland NewChief Human Resources Officer and Executive Vice President - Communications and Project Management OfficeHarry R. Gill IIISenior Vice President - Quality and Continuous ImprovementMore ExecutivesKey CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPOncoSec MedicalNASDAQ:ONCSQView All Competitors PTHN Stock Analysis - Frequently Asked Questions How were Patheon N.V. Ordinary shares, p's earnings last quarter? Patheon N.V. Ordinary shares, p (NYSE:PTHN) announced its earnings results on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01. The business had revenue of $483.40 million for the quarter, compared to analyst estimates of $466.08 million. The company's revenue for the quarter was up 3.2% compared to the same quarter last year. What other stocks do shareholders of Patheon N.V. Ordinary shares, p own? Based on aggregate information from My MarketBeat watchlists, some companies that other Patheon N.V. Ordinary shares, p investors own include SVB Financial Group (SIVB), Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Alexion Pharmaceuticals (ALXN), NXP Semiconductors (NXPI), Bank of the Ozarks (OZRK), Clearside Biomedical (CLSD), Coherus BioSciences (CHRS), Gemphire Therapeutics (GEMP) and JetBlue Airways (JBLU). When did Patheon N.V. Ordinary shares, p IPO? Patheon N.V. Ordinary shares, p (PTHN) raised $625 million in an IPO on Thursday, July 21st 2016. The company issued 30,500,000 shares at a price of $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities served as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers. This page (NYSE:PTHN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Patheon N.V. Ordinary shares, p Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.